Cadila + Glenmark Pharma – Dose for your Portfolio
Citigroup has reiterated OVERWEIGHT on Cadila Healthcare and Glenmark Pharmaceuticals with a BUY recommendation.
Cadila Healthcare:
Cadila continues to make progress in its effort to consolidate its position across key markets of US, Brazil, France & India. The adverse impact of generic competition for Protonix in the US on its JV with Nycomed is reflected in financials & valuations. Excluding a mark to market forex loss of Rs47m incurred in 4Q, FY08 results were in-line with expectations. Sales growth of 26%, EBIDTA margin expansion of 53bps & recurring (more…)